Laura Banov

Laura Banov

Auto-generated profile, based on publicly available information

Laura Banov

Hemostasis and Thrombosis Center, Department of Hematology and Oncology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Maurizio MianoMaurizio Miano
Maurizio Miano
MSMaria Scalzone
Maria Scalzone
KPKatia Perri
Katia Perri
EPElena Palmisani
Elena Palmisani
ICIlaria Caviglia
Ilaria Caviglia
FFFrancesca Fioredda
Francesca Fioredda

Verified
Journal Article
Open access
PDF file
MBMarta Bertamino
Marta Bertamino
FRFrancesca Riccardi
Francesca Riccardi
LBLaura Banov
Laura Banov
JSJohanna Svahn
Johanna Svahn
Angelo Claudio MolinariAngelo Claudio Molinari
Angelo Claudio Molinari
Hemophilia is the most common of the severe bleeding disorders and if not properly managed since early infancy can lead to chronic disease and lifelong disabilities. However, it enjoys the most efficacious and safe treatment among the most prevalent monogenic disorders. Hemophilia should be considered in the neonatal period in the case of unusual bleeding or in the case of positive family history. Later, hemophilia should be suspected mainly in males because of abnormal bruising/bleeding or unusual bleeding following invasive procedures—for example, tonsillectomy or circumcision. Prophylactic treatment that is started early with clotting-factor concentrates has been shown to prevent hemophilic arthropathy and is, therefore, the gold standard of care for hemophilia A and B in most countries with adequate resources. Central venous access catheters and arterovenous fistulas play an important role in the management of hemophilia children requiring repeated and/or urgent administration of coagulation factor concentrates. During childhood and adolescence, personalized treatment strategies that suit the patient and his lifestyle are essential to ensure optimal outcomes. Physical activity is important and can contribute to better coordination, endurance, flexibility and strength. The present article focuses also on questions frequently posed to pediatric hematologists like vaccinations, day-care/school access and dental care.


30 June 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Maurizio MianoMaurizio Miano
Maurizio Miano
MCMichaela Calvillo
Michaela Calvillo
EPElena Palmisani
Elena Palmisani
FFFrancesca Fioredda
Francesca Fioredda
CMConcetta Micalizzi
Concetta Micalizzi
CDCarlo Dufour
Carlo Dufour

17 October 2014 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
Angelo Claudio MolinariAngelo Claudio Molinari
Angelo Claudio Molinari
LBLaura Banov
Laura Banov
MBMarta Bertamino
Marta Bertamino
PBPaola Barabino
Paola Barabino
GLGiuseppe Lassandro
Giuseppe Lassandro
Paola GiordanoPaola Giordano
Paola Giordano
Low-molecular weight heparins are currently the most commonly used anticoagulants in children and newborns. However, since thrombotic complications rarely occur outside large children's hospitals, physicians often encounter some practical problems in managing these treatments when a pediatric thrombosis specialist is not available. The drug of choice is enoxaparin, due to its favorable FXa/FIIa ratio and the availability of pharmacokinetic and pharmacodynamic data. The treatment of acute thrombosis should be started with two daily injections but when compliance is an issue, a single daily administration schedule could be chosen for secondary prophylaxis ensuring careful measurement of the post 24-hour anti-FXa activity. Furthermore, a subcutaneous device may be a useful tool and a topical dermal anesthetic could be effective in controlling pain without affecting anti-FXa levels. In neonate and toddlers, where mini doses are frequently needed, the dead space of syringes and needles could represent an issue and therefore the use of insulin syringes without dead space is advisable, while a dilution of the drug is useful with other syringes. This article derives from a nonsystematic review of the available literature, with special attention to recent international guidelines and expert recommendations, combined to authors' clinical practice in large tertiary pediatric hospitals and will provide concise and practical information for the use of low-molecular weight heparin in childhood and infancy in a sort of "answering frequently asked questions."

7 August 2009 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MFMaura Faraci
Maura Faraci
ELEdoardo Lanino
Edoardo Lanino
CMConcetta Micalizzi
Concetta Micalizzi
GMGiuseppe Morreale
Giuseppe Morreale
DMDaniela Di Martino
Daniela Di Martino
APAlessandro Plebani
Alessandro Plebani